ARTICLE | Clinical News
IL-12 and IFN-a: Started Phase II trial
January 2, 2001 8:00 AM UTC
Valentis Inc. (VLTS), Burlingame, Calif. Product: IL-12 and IFN-a gene medicine in a polymeric delivery system Business: Cancer, Gene/Cell therapy Therapeutic category: Gene therapy, Immune stimulatio...